Targeting VEGF-B as a novel treatment for insulin resistance and type 2 diabetes

Nature

Volumn 490, Issue 7420, 2012, Pages 426-430

  Hagberg, Carolina E ^a,b   Mehlem, Annika ^a   Falkevall, Annelie ^a,b   Muhl, Lars ^a,b   Fam, Barbara C ^c   Ortsäter, Henrik ^a   Scotney, Pierre ^d   Nyqvist, Daniel ^a   Samén, Erik ^a,e   Lu, Li ^e   Stone Elander, Sharon ^a,e   Proietto, Joseph ^c   Andrikopoulos, Sofianos ^c   Sjöholm, Åke ^a   Nash, Andrew ^d   Eriksson, Ulf ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (Sweden)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d CSL LIMITED   (Australia)

^e KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; VASCULOTROPIN B;

BIOACCUMULATION; BIOLOGICAL UPTAKE; DIABETES; DIET; DISEASE PREVALENCE; FATTY ACID; GLUCOSE; INHIBITION; LIPID; SENSITIVITY ANALYSIS; SOCIOECONOMIC STATUS; TOLERANCE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG INHIBITION; DRUG TARGETING; DYSLIPIDEMIA; GENE DELETION; GLUCOSE TOLERANCE; GLUCOSE TRANSPORT; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIPID STORAGE; LIPID TRANSPORT; METABOLIC SYNDROME X; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ANIMALS; DIABETES MELLITUS, TYPE 2; DIET, HIGH-FAT; DISEASE MODELS, ANIMAL; DYSLIPIDEMIAS; ENDOTHELIUM, VASCULAR; FEMALE; GLUCOSE; GLUCOSE TOLERANCE TEST; INSULIN RESISTANCE; ISLETS OF LANGERHANS; LIPID METABOLISM; MALE; METABOLIC SYNDROME X; MICE; MICE, INBRED C57BL; MOLECULAR TARGETED THERAPY; MUSCLES; OBESITY; RATS; RATS, WISTAR; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR B;

MUS; RATTUS; RODENTIA;

EID: 84867672712     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature11464     Document Type: Article

References (39)

1. World Health Organization. World Health Organization Diabetes Fact sheet no. 312. http://www.who.int/mediacentre/factsheets/fs312/en/(2011).
2. Diabetes Prevention Program (DPP) Research Group. The Diabetes Prevention Pro¬gram (DPP): description of lifestyle intervention. Diabetes Care 25, 2165-2171 (2002).
3. Perseghin, G. et al. Intramyocellular triglyceride content is a determinant of in vivo insulin resistance in humans: a 1H-13C nuclear magnetic resonance spectroscopy assessment in offspring of type 2 diabetic parents. Diabetes 48, 1600-1606 (1999).
4. Samuel, V. T., Petersen, K. F. & Shulman, G. I. Lipid-induced insulin resistance: unravelling the mechanism. Lancet 375, 2267-2277 (2010).
5. Unger, R. H. Lipotoxic diseases. Annu. Rev. Med. 53, 319-336 (2002).
6. Stumvoll, M., Goldstein, B. J. & van Haeften, T. W. Type 2 diabetes: principles of pathogenesis and therapy. Lancet 365, 1333-1346 (2005).
7. Hagberg, C. E. et al. Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 464, 917-921 (2010).
8. Zimmet, P., Alberti, K. G. & Shaw, J. Global and societal implications of the diabetes epidemic. Nature 414, 782-787 (2001).
9. Schmitz-Peiffer, C. et al. Alterations in the expression and cellular localization of protein kinase C isozymes epsilon and theta are associated with insulin resistance in skeletal muscle of the high-fat-fed rat. Diabetes 46, 169-178 (1997).
10. Schmitz-Peiffer, C. Targeting ceramide synthesis to reverse insulin resistance. Diabetes 59, 2351-2353 (2010).
11. Boström, P. et al. SNARE proteins mediate fusion between cytosolic lipid droplets and are implicated in insulin sensitivity. Nature Cell Biol. 9, 1286-1293 (2007).
12. Bostrom, P. et al. The SNARE protein SNAP23 and the SNARE-interacting protein Munc18c in human skeletal muscle are implicated in insulin resistance/type 2 diabetes. Diabetes 59, 1870-1878 (2010)
13. Muoio, D. M. Metabolism and vascular fatty acid transport. N. Engl. J. Med. 363, 291-293 (2010).
14. Lahteenvuo, J. E. et al. Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1-and neuropilin receptor-1-dependent mechanisms. Circulation 119, 845-856 (2009).
15. Olofsson, B. et al. Vascular endothelial growth factor B, a novel growth factor for endothelial cells. Proc. Natl Acad. Sci. USA 93, 2576-2581 (1996).
16. Albrecht, I. et al. Suppressive effects of vascular endothelial growth factor-B on tumor growth in a mouse model of pancreatic neuroendocrine tumorigenesis. PLoS ONE 5, e14109 (2010).
17. Olofsson, B. et al. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc. Natl Acad. Sci. USA 95, 11709-11714 (1998).
18. Makinen, T. et al. Differential binding of vascular endothelial growth factor B splice andproteolyticisoformstoneuropilin-1. J. Biol. Chem. 274, 21217-21222 (1999).
19. Aase, K. et al. Vascular endothelial growth factor-B-deficient mice display an atrial conduction defect. Circulation 104, 358-364 (2001).
20. Karpanen, T. et al. Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipidmetabolismand inducesmyocardial hypertrophy. Circ. Res. 103, 1018-1026 (2008).
21. Genuth, S. M., Przybylski, R. J. & Rosenberg, D. M. Insulin resistance in genetically obese, hyperglycemic mice. Endocrinology 88, 1230-1238 (1971).
22. Sparks, L. M. et al. A high-fat diet coordinately downregulates genes required for mitochondrial oxidative phosphorylation in skeletal muscle. Diabetes 54, 1926-1933 (2005).
23. Mootha, V. K. et al. PGC-1a-responsive genes involvedinoxidative phosphorylation are coordinately downregulated in human diabetes. Nature Genet. 34, 267-273 (2003).
24. Randle, P. J. Regulatory interactions between lipids and carbohydrates: the glucose fatty acid cycle after 35 years. Diabetes Metab. Rev. 14, 263-283 (1998).
25. Eckel, R. H., Grundy, S. M. & Zimmet, P. Z. The metabolic syndrome. Lancet 365, 1415-1428 (2005).
26. Scotney, P. D. et al. Human vascular endothelial growth factor B: characterization of recombinant isoforms and generation of neutralizing monoclonal antibodies. Clin. Exp. Pharmacol. Physiol. 29, 1024-1029 (2002).
27. Fujimoto, W. Y. The importance of insulin resistance in the pathogenesis of type 2 diabetes mellitus. Am. J. Med. 108 (suppl. 6a), 9-14 (2000).
28. Chaggar, P. S., Shaw, S. M. & Williams, S. G. Review article: thiazolidinediones and heart failure. Diab. Vasc. Dis. Res. 6, 146-152 (2009).
29. Kim, F. et al. Vascular inflammation, insulin resistance, and reduced nitric oxide production precede the onset ofperipheral insulin resistance. Arterioscler. Thromb. Vasc. Biol. 28, 1982-1988 (2008).
30. Kubota, T. et al. Impaired insulin signaling in endothelial cells reduces insulin-induced glucose uptake by skeletal muscle. Cell Metab. 13, 294-307 (2011).
31. Andrikopoulos, S., Blair, A. R., Deluca, N., Fam, B. C. & Proietto, J. Evaluating the glucose tolerance test in mice. Am. J. Physiol. Endocrinol. Metab. 295, E1323-E1332 (2008).
32. Mangiafico, S. P. et al. A primary defect in glucose production alone cannot induce glucose intolerance without defects in insulin secretion. J. Endocrinol. 210, 335-347 (2011).
33. Wong, N. et al. Deficiency in interferon-c results in reduced body weight and better glucose tolerance in mice. Endocrinology 152, 3690-3699 (2011).
34. Nyqvist, D., Kohler, M., Wahlstedt, H. & Berggren, P. O. Donor islet endothelialcells participate in formation of functional vessels within pancreatic islet grafts. Diabetes 54, 2287-2293 (2005).
35. Kawasaki, F., Matsuda, M., Kanda, Y., Inoue, H. & Kaku, K. Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am. J. Physiol. Endocrinol. Metab. 288, E510-E518 (2005).
36. Lamont, B. J. et al. Peripheral insulin resistance develops in transgenic rats overexpressing phosphoenolpyruvate carboxykinase in the kidney. Diabetologia 46, 1338-1347 (2003).
37. Visinoni, S. et al. Increased glucose production in mice overexpressing human fructose-1, 6-bisphosphatase in the liver. Am. J. Physiol. Endocrinol. Metab. 295, E1132-E1141 (2008).
38. Kraegen, E. W. et al. Development of muscle insulin resistance after liver insulin resistance in high-fat-fed rats. Diabetes 40, 1397-1403 (1991).
39. Nolan, C. J. & Proietto, J. The feto-placental glucose steal phenomenon is a major cause of maternal metabolic adaptation during late pregnancy in the rat. Diabetologia 37, 976-984 (1994).